Breast cancer prevention by antiestrogens

Annals of the New York Academy of Sciences

Volumn 889, Issue , 1999, Pages 146-151

  Osborne, Michael P ^a  

^a Strang Cornell Breast Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN;

ADULT; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CATARACT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; RISK BENEFIT ANALYSIS; STROKE;

EID: 0033426936     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb08732.x     Document Type: Conference Paper

References (15)

1. 1. Osborne, M.P. & J.P. Crowe. 1987. The identificaiton of enhanced risk patients and their management in a special surveillance breast clinic. In Breast Cancer: Diagnosis and Treatment. I.M. Ariel & J.B. Cleary, Eds.: 75-86, McGraw Hill. New York.
2. 2. Simmons, R.M. & M.P. Osborne. 1999. Prophylactic mastectomy. Breast J. 3: 372-379.
3. 3. Hartman, L.C., D.J. Schaid, J.E. Woods et al. 1999. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340: 77-84.
4. 4. Jordan, V.C. 1976. Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer 12: 419-424.
5. 5. Jordan, V.C., M.K. Lababidi & M.K Langan-Fahey. 1991. Suppression of mouse mammary tumorgenesis by long-term tamoxifen therapy. J. Natl. Cancer Inst. 83: 492-496.
6. 6. Osborne, M.P., J.F. Ruperto, J.P. Crowe et al. 1992. The effect of tamoxifen on preneoplastic cell proliferationin N-nitroso-N-methylurea-induced mammmary carcinogenesis. Cancer Res. 52: 1477-1480.
7. 7. Early Breast Cancer Trialists Collaborative Group. 1998. Tamoxifen for early breast cancer: An overview of the randomized trial. Lancet 351: 1451-1467.
8. 8. Fisher, B., J.P Constantino, D.L. Wickerham et al. 1998. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 90: 1371-1388.
9. 9. Veronesi, U., P. Maisonneuve, A. Costa et al. 1998. Prevention of breast cancer with tamoxifen: Prelimminary findings from the Italian randomized trial among hysterectomized women. Lancet 352: 93-97.
10. 10. Powles, T., R. Eles, S. Ashley et al. 1998. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized prevention trial. Lancet 352: 98-101.
11. 11. Mitlak, B.M. & F.J. Cohen. 1997. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. Horm. Res. 48: 155-163.
12. 12. Cummings, S.R., S. Eckert, K.A. Krueger et al. 1999. The effect of raloxifene on risk of breast cancer in menopausal women. Results from the MORE randomized trial. J. Am. Med. Assoc. 281: 2189-2197.
13. 13. Jordan, V.C., J.E. Glusman, S. Eckert et al. 1998. Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter, double blind, randomized trials in ∼ 12,000 post-menopausal women [abstract]. Proc. Am. Soc. Clin. Oncol. 17: 122a.
14. 14. Pritchard, K.I. 1998. Is tamoxifen effective in prevention of breast cancer? Lancet 352: 80-81.
15. 15. Scully, R., J. Chen, A. Plug et al. 1997. Association of BRCA 1 with Rad 51 in mitotic and meiotic cells. Cell 88: 265-275.